Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porfimer sodium photodynamic therapy for unresectable cholangiocarcinoma
2004-003990-10Phase 3Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of porfimer sodium in cholangiocarcinoma (CCA) (2 arms), sponsored by Axcan Pharma Inc. Primary endpoint: Overall survival time. Started Feb 2005; status: completed.
02
Drugs
porfimer sodium
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2004-003990-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003990-10.